---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-005265"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:58:29.684386+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# BioCryst's Chief R&D Officer resigns after CEO selection process; to depart Sep 1, 2025

## Summary
- Dr. Helen Thackray resigns as Chief R&D Officer effective Sep 1, 2025, after not being selected as next CEO.
- Separation benefits include 1 year base salary, 2025 bonus (actual and target), 12 months health coverage, outplacement, accelerated equity vesting.
- Consulting agreement for transition through Dec 31, 2025: monthly fee $12,500, continued equity vesting during period.
- No disagreement cited with Board or management regarding company operations or policies.

## SEC filing metadata
- accession: 0001171843-25-005265
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184325005265/0001171843-25-005265-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184325005265/f8k_081125.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-005265
- JSON: https://secwatch.observer/filing/0001171843-25-005265.json
- Plain text: https://secwatch.observer/filing/0001171843-25-005265.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.